Incannex Healthcare (IXHL) FCF Margin (2024)
Incannex Healthcare (IXHL) posted FCF Margin of 47125.0% for Q4 2024, down 1453.34% sequentially from 3033.78% in Q3 2024.
Incannex Healthcare (IXHL) FCF Margin (2024) Analysis & Trends
Incannex Healthcare has reported FCF Margin for 1 years, with the latest figure at 47125.0% in Q4 2024.
- Quarterly FCF Margin changed N/A year-over-year to 47125.0% in Q4 2024, while the trailing twelve-month figure through Jun 2025 was 14550.0% (changed N/A YoY) and the FY2025 annual result came in at 14559.3%, up 11979070.0% from the prior year.
- FCF Margin fell to 47125.0% in Q4 2024 per IXHL's latest filing, from 3033.78% in the prior quarter.
- Over five years, FCF Margin peaked at 3033.78% in Q3 2024 and troughed at 47125.0% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Incannex Healthcare | 43.22 Mn | 43.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -47,125.00% |
| Sep 30, 2024 | -3,033.78% |